摘要
由于导致严重感染的多药耐药菌发生率上升,临床迫切需要寻求新型抗菌药物,尤其需要能够有效克服现有耐药机制的全新药物。替加环素为新型抗菌甘氨环素类药物,即米诺环素的衍生物,能够克服与四环素类绝大部分相关的耐药机制。体外试验显示替加环素尽管对铜绿假单胞菌无效,对变形杆菌属的作用较差,但对耐万古霉素肠球菌、耐甲氧西林金黄色葡萄球菌、耐青霉素肺炎链球菌和其他多药耐药革兰阴性菌均具有良好活性。Ⅲ期临床试验已就替加环素治疗由多药耐药菌引起危及生命的感染的作用进行了研究,其抗菌谱新颖广阔,具有良好的临床应用前景。
New antimicrobial agents are urgently needed for clinical use due to the increasing incidence of serious and life-threatening diseases caused by multidrug-resistant bacteria. The need to develop new agents that effectively overcome existing mechanisms of resistance to currently available drugs has become paramount. Tigecycline, the first in a new class of antimicrobials, the glycylcyclines, is an analogue of minocycline with additional properties that negate most mechanisms mediating resistance to the tetracy- clines. In vitro testing, resistance to tigecycline by Pseudomonas aeruginosa and reduced susceptibility among Proteus species do occur, but it has revealed that tigecycline has activity against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae and many species of multidrug-resistant Gram-negative bacteria. Tigecycline is being evaluated in multicentre Phase Ⅲ clinical trials for treatment of many serious and life-threatening infections in which multidrug-resistant bacterial organisms may be found. Tigecycline appears to hold promise as a novel expanded spectrum antibiotic.
出处
《国外医学（药学分册）》
2007年第2期106-109,114,共5页
Foreign Medical Sciences(Section of Pharmarcy)
关键词
感染
细菌
替加环素
甘氨环素类
infection
bacteria
tigecycline
glycylcyclines
